1-20 of 52
Bo Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3566: Expansion of the Pediatric Brain Tumor Atlas: Children's Brain Tumor Network, Kids First Data Resource and Childhood Cancer Data Initiative Open Science effort

Mateusz P. Koptyra, Komal Rahti, Yuankun Zhu, Bailey Farrow, Daniel Miller, Adam Kraya, Yiran Guo, Peter Madsen, Nicholas Van Kuren, Xiaoyan Huang, Miguel A. Brown, Jennifer L. Mason, Meen Chul Kim, Allison P. Heath, Brian M. Ennis, Bo Zhang, Jena V. Lilly, Jo Lynne Rokita, Christopher Friedman, Ximena P. Cuellar, Catherine A. Sullivan, Noel Coleman, Trang Duros, Thinh Q. Nguyen, Emmett C. Drake, Zeinab Helili, Beth A. Frenkel, Gerri R. Trooskin, Ariana Familiar, Karthik Viswanathan, Christopher M. Beck, Madison L. Hollawell, Valerie P. Baubet, Cassie Kline, Mariarita Santi, Tatiana S. Patton, Stephanie Stefankiewicz, Arya Kamnaa, Ryan A. Velasco, Dani Cardona, Phillip J. Storm, Adam C. Resnick, o/b/o Children's Brain Tumor Network
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3566.
https://doi.org/10.1158/1538-7445.AM2023-3566
Published: 04 April 2023
View article titled, Abstract 3566: Expansion of the Pediatric Brain Tumor Atlas: Children's Brain Tumor Network, Kids First Data Resource and Childhood Cancer Data Initiative Open Science effort
Journal Articles

Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma

Bo Zhang, Hui Peng, Mi Zhou, Lei Bao, Chenliang Wang, Feng Cai, Hongxia Zhang, Jennifer E. Wang, Yanling Niu, Yan Chen, Yijie Wang, Kimmo J. Hatanpaa, John A. Copland, Ralph J. DeBerardinis, Yingfei Wang, Weibo Luo
Journal: Cancer Research
Cancer Res (2022) 82 (13): 2388–2402.
https://doi.org/10.1158/0008-5472.CAN-21-3868
Published: 05 July 2022
View article titled, Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma
Open the PDF for Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract 5541: BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models

Ye Liu, Jing Li, Zhuo Li, Qin Wang, Xing Zhou, Xiaoxin Liu, Bo Zhang, Xitao Wang, Sanjia Xu, Hanzi Sun, Xiaomin Song, Xi Yuan, Zhiwei Wang, Xuesong Liu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5541.
https://doi.org/10.1158/1538-7445.AM2022-5541
Published: 15 June 2022
View article titled, Abstract 5541: BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
Journal Articles

Abstract 5249: Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study

Jun Liu, Guangbing Li, Qiang He, Shijun Sun, Chuanlin Zhao, Chuandong Sun, Bo Zhang, Yi Cui, Yongqiang Ye, Xuting Zhi, Shiping Li, Shiping Li, Guozheng Pan, Changlin Ma, Jinhua Hu, Jun Li, Suling Wang, Yuangang Qiao, Wanhua Ren, Qi Meng
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5249.
https://doi.org/10.1158/1538-7445.AM2022-5249
Published: 15 June 2022
View article titled, Abstract 5249: Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study
Journal Articles

Correction: Cytoplasmic Irradiation Results in Mitochondrial Dysfunction and DRP1-Dependent Mitochondrial Fission

Bo Zhang, Mercy M. Davidson, Hongning Zhou, Chunxin Wang, Winsome F. Walker, Tom K. Hei
Journal: Cancer Research
Cancer Res (2022) 82 (6): 1154.
https://doi.org/10.1158/0008-5472.CAN-21-4330
Published: 15 March 2022
View article titled, Correction: Cytoplasmic Irradiation Results in Mitochondrial Dysfunction and DRP1-Dependent Mitochondrial Fission
Open the PDF for Correction: Cytoplasmic Irradiation Results in Mitochondrial Dysfunction and DRP1-Dependent Mitochondrial Fission in another window
Journal Articles

Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Komal Jhaveri, Haeseong Park, James Waisman, Jonathan W Goldman, Angel Guerrero-Zotano, Valentina Boni, Barbara Haley, Ingrid A Mayer, Adam Brufsky, Eddy S Yang, José A García-Sáenz, François-Clement Bidard, John Crown, Bo Zhang, Aimee Frazier, Irmina Diala, Lisa D Eli, Brian Barnett, Hans Wildiers
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS4-10.
https://doi.org/10.1158/1538-7445.SABCS21-GS4-10
Published: 15 February 2022
View article titled, Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, <em>HER2</em>-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
Journal Articles

Abstract P5-13-20: Identifying a metabolite signature that correlates with tumor proliferation in early-stage breast cancer patients treated with CDK4/6 inhibitors from matched plasma and serum samples

Chen Dong, Shana Thomas, Chandrashekhar Honrao, Leonardo O. Rodrigues, Nathalie Tessier, Bo Zhang, Souzan Sanati, Kiran Vij, Brenda J. Ernst, Karen S. Anderson, Mateusz Opyrchal, Foluso Ademuyiwa, Lindsay L. Peterson, Matthew P. Goetz, Donald Northfelt, Elizabeth O'Day, Cynthia Ma
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-20.
https://doi.org/10.1158/1538-7445.SABCS21-P5-13-20
Published: 15 February 2022
View article titled, Abstract P5-13-20: Identifying a metabolite signature that correlates with tumor proliferation in early-stage breast cancer patients treated with CDK4/6 inhibitors from matched plasma and serum samples
Journal Articles

Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial

Frankie Ann Holmes, Debra Patt, Yvonne Manalo, Julie C Smith, Steven W Papish, Noa Efrat, Ana Arance, Bo Zhang, Deepa Lalla, Alvin Wong, Miguel Martin
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-21.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-21
Published: 15 February 2022
View article titled, Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial
Journal Articles

A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression

Shuhang Liang, Hongrui Guo, Kun Ma, Xianying Li, Dehai Wu, Yiqi Wang, Wei Wang, Shugeng Zhang, Yifeng Cui, Yufeng Liu, Linmao Sun, Bo Zhang, Mengyang Xin, Ning Zhang, Huanran Zhou, Yao Liu, Jiabei Wang, Lianxin Liu
Journal: Cancer Research
Cancer Res (2021) 81 (23): 5889–5903.
https://doi.org/10.1158/0008-5472.CAN-21-1538
Published: 01 December 2021
View article titled, A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression
Open the PDF for A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression in another window
Includes: Supplementary data
Journal Articles

Abstract PO-057: Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit the metastasis of pancreatic cancer

Bo Zhang, Fei Teng, Nengming Lin
Journal: Cancer Research
Cancer Res (2021) 81 (22_Supplement): PO-057.
https://doi.org/10.1158/1538-7445.PANCA21-PO-057
Published: 15 November 2021
View article titled, Abstract PO-057: Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit the metastasis of pancreatic cancer
Journal Articles

Abstract 380: WNT signal pathway activation correlates with innate resistant to immune checkpoint therapies in NSCLC

Dian Ren, Bo Zhang, Renwang Liu, Fuyu Gong, Yuezong Bai, Wenzhuan Xie, Huandong Huo, Hao Zhang, Zuoqing Song
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 380.
https://doi.org/10.1158/1538-7445.AM2021-380
Published: 01 July 2021
View article titled, Abstract 380: WNT signal pathway activation correlates with innate resistant to immune checkpoint therapies in NSCLC
Journal Articles

Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia

Hongbo Yang, Hui Zhang, Yu Luan, Tingting Liu, Kathryn Roberts, Mao-xiang Qian, Bo Zhang, Wenjian Yang, Virginia Perez-Andreu, Jie Xu, Sriranga lyyanki, Da Kuang, Shalini Reshmi, Julie Gastier-Foster, Colton Smith, Ching-Hon Pui, William Evans, Stephen Hunger, Stephen Hunger, Leonidas Platanias, Mary Relling, Charles Mullighan, Mignon Loh, Feng Yue, Jun Yang
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2118.
https://doi.org/10.1158/1538-7445.AM2021-2118
Published: 01 July 2021
View article titled, Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia
Journal Articles

Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

Beverly Moy, Mafalda Oliveira, Cristina Saura, William Gradishar, Sung-Bae Kim, Adam Brufsky, Sara Hurvitz, Larisa Ryvo, Daniele Fagnani, Nancy Chan, Sujith R Kalmadi, Paula Silverman, Suzette Delaloge, Richard Bryce, Kiana Keyvanjah, Judith Bebchuk, Bo Zhang, Nina Oestreicher, Ron Bose
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS9-02.
https://doi.org/10.1158/1538-7445.SABCS20-PS9-02
Published: 15 February 2021
View article titled, Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens
Journal Articles

ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth

Yong Wang, Maowu Luo, Yan Chen, Yijie Wang, Bo Zhang, Zhenhua Ren, Lei Bao, Yanan Wang, Jennifer E. Wang, Yang-Xin Fu, Weibo Luo, Yingfei Wang
Journal: Cancer Research
Cancer Res (2021) 81 (1): 174–186.
https://doi.org/10.1158/0008-5472.CAN-20-1710
Published: 04 January 2021
View article titled, ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth
Open the PDF for ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth in another window
Includes: Supplementary data
Journal Articles

CHD4 Promotes Breast Cancer Progression as a Coactivator of Hypoxia-Inducible Factors

Yijie Wang, Yan Chen, Lei Bao, Bo Zhang, Jennifer E. Wang, Ashwani Kumar, Chao Xing, Yingfei Wang, Weibo Luo
Journal: Cancer Research
Cancer Res (2020) 80 (18): 3880–3891.
https://doi.org/10.1158/0008-5472.CAN-20-1049
Published: 15 September 2020
View article titled, CHD4 Promotes Breast Cancer Progression as a Coactivator of Hypoxia-Inducible Factors
Open the PDF for CHD4 Promotes Breast Cancer Progression as a Coactivator of Hypoxia-Inducible Factors in another window
Includes: Supplementary data
Journal Articles

HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis

Yanling Niu, Lei Bao, Yan Chen, Chenliang Wang, Maowu Luo, Bo Zhang, Mi Zhou, Jennifer E. Wang, Yisheng V. Fang, Ashwani Kumar, Chao Xing, Yingfei Wang, Weibo Luo
Journal: Cancer Research
Cancer Res (2020) 80 (5): 964–975.
https://doi.org/10.1158/0008-5472.CAN-19-1532
Published: 02 March 2020
View article titled, HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis
Open the PDF for HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis in another window
Includes: Supplementary data
Journal Articles

Abstract P4-10-25: Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer

Elizabeth O’Day, Kim Leitzel, Suhail M Ali, Bo Zhang, Chen Dong, Haiwei Gu, Xiajian Shi, Joseph J Drabick, Leah Cream, Monali Vasekar, Hyma V Polimera, Vinod Nagabhairu, Prashanth Moku, Ashok Maddukuri, Harry Menon, Neha Pancholy, Walter P Carney, Wolfgang Koestler, Allan Lipton
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-10-25.
https://doi.org/10.1158/1538-7445.SABCS19-P4-10-25
Published: 15 February 2020
View article titled, Abstract P4-10-25: Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer
Journal Articles

Correction: Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation–Induced Immune Suppression

Wei Wang, Nicole M. Chapman, Bo Zhang, Mingqi Li, Meiyun Fan, R. Nicholas Laribee, M. Raza Zaidi, Lawrence M. Pfeffer, Hongbo Chi, Zhao-Hui Wu
Journal: Cancer Research
Cancer Res (2019) 79 (21): 5682.
https://doi.org/10.1158/0008-5472.CAN-19-2862
Published: 01 November 2019
View article titled, Correction: Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation–Induced Immune Suppression
Open the PDF for Correction: Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation–Induced Immune Suppression in another window
Journal Articles

Abstract 2620: Global epigenetic regulation of gene expression and tumor suppression in T-cell leukemia by Ikaros

Yali Ding, Bo Zhang, Jonathon L. Payne, Kimberly J. Payne, Chunhua Song, Chandrika Gowda, Soumya Iyer, Pavan K. Dhanyamraju, Dhimant Desai, Suming Huang, Feng Yue, Sinisa Dovat
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2620.
https://doi.org/10.1158/1538-7445.AM2019-2620
Published: 01 July 2019
View article titled, Abstract 2620: Global epigenetic regulation of gene expression and tumor suppression in T-cell leukemia by Ikaros
Journal Articles

Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab

Yingcai Feng, Yuan Hong, Hanzi Sun, Bo Zhang, Hongfu Wu, Kang Li, Xuesong (Mike) Liu, Ye Liu
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2383.
https://doi.org/10.1158/1538-7445.AM2019-2383
Published: 01 July 2019
View article titled, Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab